Effects of parenteral nutrition with Olive and Soybean based lipid emulsions on oxidative stress and inflammatory response in severe acute pancreatitis

Effects of parenteral nutrition with Olive and Soybean based lipid emulsions on oxidative stress and inflammatory response in severe acute pancreatitis: A prospective, controlled, randomized,blinded, paralleled study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001346

Enrollment

Unknown

Registered

2011-03-02

Start date

2011-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe acute pancreatitis

Interventions

study group:All-in-one bags,fat emulsion is olive oil(ClinOleic)

control group:All-in-one bags,fat emulsion is soybean oil(Intralipid)

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Male or female with the age between 18 and 75 years old; 2. Agree to participate by signing an informed consent form; 3. SAP admitted to hospital within 72 hours after onset of SAP; 4. No PN support contraindications; 5. Patient's hospitalization is required for at least 9 days, and parenteral nutrition for 7 days or more.

Exclusion criteria

Exclusion criteria: 1. Admitted to the hospital after 72 hours of SAP onset; 2. Participation in another investigational drug study in the last 4 weeks before selection; 3. Lipids infusion for nutrition purpose in the past one day; 4. Participated this study before; 5. Expected life span is less than 7 days; 6. Known pregnancy or breast feeding period; 7. Severe complications related with anaesthesia or operation. 8. Known anaphylactic to any component of lipid emulsion (egg, soy protein, etc); 9. Contraindication to parenteral nutrition (dyscoagulation, metabolic disorders that can not be corrected, etc.); 10. Patients with hyper triglyceridemia characterized by triglyceridemia >5.1mmol/L, or Total cholesterol >12mmol/L; 11. Patients with Chronic liver disease characterized by AST more than 2 times normal levels or severe cholestasis characterized by conjugated bilirubine more than 2 times normal levels; 12. Severe cardiac or pulmonary insufficiency; 13. Chronic renal insufficiency characterized by both BUN and creatine> 2 times normal levels; 14. Known HIV infection; 15. The use of insulin, corticoids, cytostatics, cyclooxygenase inhibitors within 2 weeks prior to the study.

Design outcomes

Primary

Measure	Time frame
Oxidative stress measurement;	—

Secondary

Measure	Time frame
immune measurements;clinical outcom;	—

Countries

China

Contacts

Public ContactWei CHEN, XiuRong WANG

txchenwei@gmail.com+86 10 65294095

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026